SenesTech - SNES Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SenesTech in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" SNES shares.
View SNES analyst ratings or view top-rated stocks.

SenesTech's stock was trading at $3.09 at the start of the year. Since then, SNES shares have decreased by 47.2% and is now trading at $1.63.
View the best growth stocks for 2023 here.

SenesTech saw a decline in short interest in February. As of February 28th, there was short interest totaling 16,500 shares, a decline of 45.7% from the February 13th total of 30,400 shares. Based on an average daily volume of 160,300 shares, the days-to-cover ratio is presently 0.1 days. Currently, 2.6% of the shares of the company are short sold.
View SenesTech's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023.
View our SNES earnings forecast.

SenesTech, Inc. (NASDAQ:SNES) announced its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.09). The business earned $0.18 million during the quarter, compared to the consensus estimate of $0.22 million. SenesTech had a negative trailing twelve-month return on equity of 177.67% and a negative net margin of 951.42%. During the same quarter last year, the business earned ($0.28) EPS.

Shares of SenesTech split on Thursday, September 1st 2022. The 2-1 split was announced on Thursday, September 1st 2022. The newly minted shares were payable to shareholders after the closing bell on Thursday, September 1st 2022. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other SenesTech investors own include TransEnterix (TRXC), Carrizo Oil & Gas (CRZO), Auris Medical (EARS), Marathon Oil (MRO), Adamis Pharmaceuticals (ADMP), McDermott International (MDR), ZIOPHARM Oncology (ZIOP), Citius Pharmaceuticals (CTXR) and DURECT (DRRX).

(SNES) raised $15 million in an initial public offering (IPO) on Thursday, December 8th 2016. The company issued 1,900,000 shares at $8.00 per share. Roth Capital Partners served as the underwriter for the IPO and Craig-Hallum Capital Group was co-manager.

SenesTech trades on the NASDAQ under the ticker symbol "SNES."

SenesTech's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Armistice Capital LLC (11.82%).
View institutional ownership trends.

Shares of SNES stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SNES stock can currently be purchased for approximately $1.63.

SenesTech (NASDAQ:SNES) has a market capitalization of $994,300.00 and generates $1.02 million in revenue each year. The company earns $-9,690,000.00 in net income (profit) each year or ($16.60) on an earnings per share basis.

SenesTech's mailing address is 23460 NORTH 19TH AVENUE SUITE 110, PHOENIX AZ, 85027. The official website for the company is www.senestech.com. The company can be reached via phone at (928) 779-4143 or via email at senestech@lythampartners.com.